Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Intravenous replenishment of fluids and calories in patients who cannot take orally,Maintenance of hydration and electrolyte balance,Treatment of hypovolemia,Prevention of dehydration
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
The terminal half-life of infused dextrose is not applicable as glucose is rapidly metabolized; however, exogenous glucose infusion is cleared with a half-life of approximately 15-30 minutes due to insulin-mediated uptake. Sodium and chloride have no defined elimination half-life as they are homeostatically regulated.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Dextrose is metabolized via glycolysis and the Krebs cycle in cells; sodium and chloride are excreted renally and via sweat; no significant hepatic metabolism.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Dextrose is completely metabolized to carbon dioxide and water, with negligible renal excretion of intact glucose under normal conditions. Sodium and chloride are freely filtered by the glomerulus and undergo variable tubular reabsorption; excess is excreted renally. No biliary or fecal elimination.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Dextrose: not bound to plasma proteins. Sodium: negligible protein binding. Chloride: not significantly protein bound.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Dextrose distributes into total body water, approximately 0.55-0.6 L/kg in adults. Sodium and chloride distribute primarily into extracellular fluid, with volumes of distribution of approximately 0.2 L/kg for sodium and 0.25 L/kg for chloride. These reflect rapid equilibration in respective compartments.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% for dextrose, sodium, and chloride. Not applicable for other routes as this formulation is for IV use only.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR <10 m L/min: Avoid or use with caution due to risk of fluid overload and hypernatremia. GFR 10-50 m L/min: Monitor serum sodium and fluid status; adjust rate as needed. No specific dose reduction, but infusion rate may need to be decreased.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment required for Child-Pugh class A or B. For Child-Pugh class C: Use with caution due to potential fluid retention; monitor serum sodium and adjust rate accordingly.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 2-4 m L/kg/hour for children. For neonates, rate may be adjusted to 80-100 m L/kg/day. Do not exceed 25 m L/kg/hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients: Start at lower end of dosing range (e.g., 100 m L/hour) and titrate based on fluid status, renal function, and cardiac reserve. Monitor for signs of fluid overload and electrolyte imbalance.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn-derived products. Do not administer to patients with anuria. Use with caution in patients with congestive heart failure, renal failure, or hyperglycemia.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hyperglycemia and hyperosmolarity, especially in diabetic or stressed patients,Monitor serum glucose and electrolytes,Use with caution in renal impairment, heart failure, and increased intracranial pressure,Hypotonic solution; may cause hemolysis if administered rapidly,Do not use if solution is discolored or contains particulates
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to dextrose or corn products,Intracranial or intraspinal hemorrhage,Anuria,Severe hyperglycemia with marked glycosuria,Patients with known allergy to any component
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, patients should avoid excessive salt or sugar intake unless directed by a healthcare provider.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. Hyperglycemia or fluid/electrolyte imbalances may pose fetal risks. No first trimester data suggest direct teratogenicity.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Both dextrose and sodium chloride are normal constituents of breast milk. Maternal administration at isotonic and isosmotic concentrations does not alter milk composition measurably. M/P ratio not applicable as endogenous substances. Generally considered compatible with breastfeeding.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Increased plasma volume (30-50%) and glomerular filtration rate during pregnancy may alter pharmacokinetics; however, dextrose and sodium chloride are endogenous substances regulated by homeostasis. No specific dose adjustment required except to monitor and adjust infusion rate based on maternal glucose, hydration status, and electrolyte levels. Pregnancy may unmask glucose intolerance; titrate dextrose infusion to avoid hyperglycemia.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Dextrose 5% and sodium chloride 0.45% is a hypotonic solution. Use cautiously in patients at risk for increased intracranial pressure (e.g., traumatic brain injury) as rapid administration may cause cerebral edema. Avoid in patients with hyperglycemia, as dextrose can worsen glycemic control. Monitor serum sodium closely in patients with impaired renal function or syndrome of inappropriate antidiuretic hormone (SIADH) to prevent hyponatremia.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report symptoms like headache, nausea, confusion, or swelling during the infusion.,Do not consume additional salt or sugar without medical advice while receiving this solution.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.